September 8, 2023 01:42 PM EDT
Pharma
FDA+

Citius Phar­ma­ceu­ti­cals looks to re­file for­mer Ei­sai can­cer drug in ear­ly 2024

Nicole DeFeudis

Editor

Citius Phar­ma­ceu­ti­cals plans to re­file its ex­per­i­men­tal drug for a rare blood can­cer in ear­ly 2024 fol­low­ing an FDA re­jec­tion in Ju­ly.

The drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

No­var­tis, Ab­b­Vie and PhRMA se­cure 340B court win in West Vir­ginia

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

A service from the Financial Times